Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xoma ( (XOMA) ) has issued an update.
On January 12, 2026, XOMA Royalty Corporation released an updated corporate presentation outlining its differentiated royalty-aggregation business model, current capitalization and growing portfolio of biotechnology-related royalty and milestone assets. The presentation highlighted a 2025 “year in review” marked by multiple royalty acquisitions, out-licensing deals, non-dilutive capital arrangements and significant expected tax benefits, alongside more than $140 million in milestones received since 2017 and over $2 billion in potential future milestones tied to its pipeline. Management emphasized a path to sustained profitability driven by a compounding effect of increasing royalty streams, low operating expenses and a relatively low share count, and pointed to 2026 as a catalyst-rich year, with several key regulatory decisions, late-stage data readouts and product launches in partnered programs that could materially influence future cash flows and enterprise value for shareholders.
The most recent analyst rating on (XOMA) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Xoma stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
The score is held back primarily by balance-sheet leverage and weak cash-flow signals despite strong reported profitability. Technical indicators are mixed with negative momentum versus mid-term averages, while valuation appears high at a 36.5 P/E without a dividend. A positive offset is the completed acquisition supporting the company’s stated portfolio-expansion strategy.
To see Spark’s full report on XOMA stock, click here.
More about Xoma
XOMA Royalty Corporation, listed on Nasdaq, operates as a biotech-focused royalty aggregator that acquires milestone and royalty interests in early- to mid-stage clinical and commercial drug candidates. The company targets smaller transactions than many larger royalty competitors, concentrating on a diversified portfolio of more than 100 assets across preclinical, clinical and commercial stages, and finances its activities with a mix of common equity, perpetual preferred shares and royalty-backed debt.
Average Trading Volume: 157,087
Technical Sentiment Signal: Buy
Current Market Cap: $370.5M
Learn more about XOMA stock on TipRanks’ Stock Analysis page.